Tofogliflozin attenuates liver steatosis and fibrosis in non-diabetic non-alcoholic steatohepatitis mice
Yoshinori Ozono, Hiroshi Kawakami, Hiroshi Hatada, Naomi Uchiyama et autres
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease with increasing global prevalence. Although diabetes is a major factor in NAFLD progression, up to 75% of the patients with NAFLD do not have diabetes. Tofogliflozin (Tofo), a …
jp (code pays fourni par la source)
0 citations
BMC Gastroenterology